Kerry’s primary focus is patent drafting, prosecution, opposition and appeals before the European Patent Office but he also has extensive experience in all phases of foreign patent prosecution. He also provides FTO/infringement advice.
He undertakes work in a wide variety of technology areas including pharmaceuticals, biologicals, chemistry and biochemistry, microbiology, cell and molecular biology, immunology and medical devices.
Kerry has a particular interest in food technology, including alt proteins, fermentation, cultured meat and cellular agriculture, food ingredients, food feed and food enzymology, advising a variety of companies at various stages of development on IP strategies to attract funding or IP due diligence in preparing for acquisition, and advising on proactive attacking or defensive strategies in relation to third party IP.
Kerry acts for a wide range of clients including start-ups and investors, research institutions, universities and spin-outs, mid-size companies and international corporations.
Kerry works with private equity and venture capital investors to assess and mitigate IP risks associated with an investment. Kerry particularly enjoys working with investee companies to develop IP strategies which support the business plan and to secure commercially relevant IP whether that be to secure funding or increase growth and market share.
Molecular and Cellular Biochemistry, University of Oxford
Certificate in Intellectual Property Law, University of London
May 18th 2021
December 2nd 2020
November 20th 2020
September 11th 2020
September 2nd 2020
Managing Intellectual Property IP Stars 2021, comprising the highly recommended IP professionals, has now been published. HGF is delighted to have 14 European attorneys listed. IP STARS is the leading …Read article
Pharmaceutical and biotechnology patent applications also make top 10 most patented. Recent statistics published by the EPO show that a total of 14,295 European patent applications were filed in 2020 …Read article
The 2021 EPO Guidelines provide much needed guidance on how to protect antibodies in Europe. Biological drugs including therapeutic antibodies have become increasingly important to the pharmaceutical industry. The European …Read article
Opportunities for additional pharmaceutical product patent protection in Europe, based on the use of a drug to treat a patient exhibiting a biomarker indicative of drug response. Recent years have …Read article
Exploring the growth of patents for connected medical devices, and how best to protect them. The Internet of Things (IoT) is expected to change our lives by creating a connected …Read article
To waive, or not to waive, that is the question. The earliest identified date of a patient presenting with symptoms of a “novel coronavirus” in Wuhan, China is reported to …Read article
HGF in Europe and Knobbe Martens in the US are holding a joint webinar on 9th June. In this webinar we will explore considerations for implementing an effective strategy to …Event details
HGF Partner Dr Susan Keston and Senior Patent Attorney Dr Sofie McPherson will be presenting a webinar ‘How to capitalise on the 5G healthcare revolution’ on 25th May. This session will explore how 5G …Event details
If you would like to discuss how HGF could help you, contact one of our IP specialists.